Biotech Values

[DewDiligence]

GILD—Since you’re tooting your horn about your accurate call wrt GILD’s HCV sales and EPS, I’ll take the opportunity to toot my own horn with respect to GILD’s P/E ratio; from my post on 3/8/14 (#msg-98494046):

I think your projected P/E ratios are much too high and that a P/E of 10 is reasonable. There’s a large amount of uncertainty a few years out, particularly in the HIV business.